• +1-646-491-9876
    • +91-20-67278686

    Search

    Alpha Synuclein-Pipeline Review H2 2017

    Alpha Synuclein-Pipeline Review H2 2017

    • Report Code ID: RW0001881475
    • Category Life Sciences
    • No. of Pages 93
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)-Pipeline Review H2 2017

    Summary

    Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)-Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson's. In Parkinson's it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli leading to decreased caspase-3 activation.

    Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 37 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II Phase I Preclinical Discovery and Unknown stages are 3 5 21 2 and 1 respectively. Similarly the universities portfolio in Preclinical stages comprises 5 molecules respectively. Report covers products from therapy areas Central Nervous System Metabolic Disorders Cardiovascular Gastrointestinal Infectious Disease and Ophthalmology which include indications Parkinson's Disease Alzheimer's Disease Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Neurodegenerative Diseases Lewy body Dementia Amyloidosis Constipation Familial Amyloid Neuropathies Glaucoma Human Immunodeficiency Virus (HIV) Infections (AIDS) Huntington Disease Schizophrenia Spinal Cord Injury Stroke Traumatic Brain Injury and Type 2 Diabetes.

    The latest report Alpha Synuclein-Pipeline Review H2 2017 outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type. It also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
    - The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)-Overview
    Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)-Companies Involved in Therapeutics Development
    AC Immune SA
    AFFiRiS AG
    BioArctic AB
    Biogen Inc
    Evotec AG
    Genmab A/S
    H. Lundbeck A/S
    ICB International Inc
    MedImmune LLC
    Neuropore Therapies Inc
    nLife Therapeutics SL
    Prothena Corp Plc
    QR Pharma Inc
    reMYND NV
    Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)-Drug Profiles
    ABL-301-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antibodies to Inhibit Alpha-Synuclein for Glaucoma-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antibody to Inhibit Alpha Synuclein for Parkinson's Disease-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AV-1947D-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AV-1948D-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AV-1949D-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AV-1950D-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AV-1950R-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BAN-0805-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BIIB-054-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CLR-01-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DPC-003-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs for Parkinson's disease-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ENT-01-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LuAF-82422-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MEDI-1341-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit Tau Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit Alpha Synuclein for Parkinson's Disease-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NLFPD-1233-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NPT-088-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NPT-20011-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NPT-289-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NPT-3G-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NPT100-18A-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PD-01-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PD-03-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PD-04-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Posiphen-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PP-003-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRX-002-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    quinpramine-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ReS-9S-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    trehalose-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target Alpha-Synuclein for Neurodegenerative Disease-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)-Dormant Products
    Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)-Product Development Milestones
    Featured News & Press Releases
    Jun 08 2017 Anti-Alpha-Synuclein Antibody is a Potential Disease-Modifying Treatment for Parkinson's Disease
    Jun 07 2017 AFFiRiS Announces Top Line Results of First-in-Human Clinical Study Using AFFITOPE PD03A Confirming Immunogenicity and Safety Profile in Parkinson's Disease Patients
    May 15 2017 Enterin's RASMET Study Enrolls First Patient With Parkinson's Disease
    Apr 02 2017 Clinical Results Presented from Prothena's Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease
    Mar 28 2017 Biogen to Present Data on BIIB054 at the 13th International Conference on Alzheimer's and Parkinson's Diseases
    Mar 16 2017 QR Pharma Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference
    Mar 09 2017 Results for Prothena's Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with Parkinson's Disease to be Presented at the 13th International Conference on Alzheimer's and Parkinson's Diseases
    Dec 13 2016 First-In-Human Assessment of PRX002 Prothenas Anti-Alpha Synuclein Antibody for Parkinson's Disease Published in Movement Disorders Journal
    Nov 18 2016 Proclara Biosciences Awarded Part the Cloud Grant from Alzheimers Association to Support Development of NPT088 for Alzheimer's Disease
    Nov 16 2016 Proclara Biosciences Announces Newly Issued U.S. Patents for its Core Technology Targeting Protein Misfolding Disorders
    Nov 09 2016 Prothena Reports Results from Phase 1b Study of PRX002 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease
    Sep 07 2016 Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimer's Disease
    Mar 22 2016 Neuropore Announces Successful Completion of Phase I with its Lead Compound NPT200-11
    Aug 12 2015 Neuropore Therapies Commences Phase 1 Clinical Trials
    Jul 19 2015 NeuroPhage's NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer's Association International Conference
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indication H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Companies H2 2017 (Contd..1)
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Products under Development by Companies H2 2017 (Contd..2) H2 2017
    Number of Products under Investigation by Universities/Institutes H2 2017
    Products under Investigation by Universities/Institutes H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Pipeline by AC Immune SA H2 2017
    Pipeline by AFFiRiS AG H2 2017
    Pipeline by BioArctic AB H2 2017
    Pipeline by Biogen Inc H2 2017
    Pipeline by Evotec AG H2 2017
    Pipeline by Genmab A/S H2 2017
    Pipeline by H. Lundbeck A/S H2 2017
    Pipeline by ICB International Inc H2 2017
    Pipeline by MedImmune LLC H2 2017
    Pipeline by Neuropore Therapies Inc H2 2017
    Pipeline by nLife Therapeutics SL H2 2017
    Pipeline by Prothena Corp Plc H2 2017
    Pipeline by QR Pharma Inc H2 2017
    Pipeline by reMYND NV H2 2017
    Dormant Products H2 2017
    Dormant Products H2 2017 (Contd..1) H2 2017

    List of Figures

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Top 10 Indications H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    AC Immune SA
    AFFiRiS AG
    BioArctic AB
    Biogen Inc
    Evotec AG
    Genmab A/S
    H. Lundbeck A/S
    ICB International Inc
    MedImmune LLC
    Neuropore Therapies Inc
    nLife Therapeutics SL
    Prothena Corp Plc
    QR Pharma Inc
    reMYND NV

    Request for Sample

    Report Url http://www.reportsweb.com//alpha-synuclein-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//alpha-synuclein-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//alpha-synuclein-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments